We provide you with 20 years of free, institutional-grade data for CELC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CELC. Explore the full financial landscape of CELC stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-14 | 1603454 | CELC | 10-Q | Url |
| 2025-05-15 | 1603454 | CELC | 10-Q | Url |
| 2025-03-31 | 1603454 | CELC | 10-K | Url |
| 2024-11-14 | 1603454 | CELC | 10-Q | Url |
| 2024-08-14 | 1603454 | CELC | 10-Q | Url |
| 2024-05-15 | 1603454 | CELC | 10-Q | Url |
| 2024-03-27 | 1603454 | CELC | 10-K | Url |
| 2023-11-13 | 1603454 | CELC | 10-Q | Url |
| 2023-08-11 | 1603454 | CELC | 10-Q | Url |
| 2023-05-15 | 1603454 | CELC | 10-Q | Url |
| 2023-03-23 | 1603454 | CELC | 10-K | Url |
| 2022-11-10 | 1603454 | CELC | 10-Q | Url |
| 2022-08-12 | 1603454 | CELC | 10-Q | Url |
| 2022-05-16 | 1603454 | CELC | 10-Q | Url |
| 2022-03-23 | 1603454 | CELC | 10-K | Url |
| 2021-11-09 | 1603454 | CELC | 10-Q | Url |
| 2021-08-11 | 1603454 | CELC | 10-Q | Url |
| 2021-05-10 | 1603454 | CELC | 10-Q | Url |
| 2021-02-16 | 1603454 | CELC | 10-K | Url |
| 2020-11-09 | 1603454 | CELC | 10-Q | Url |
| 2020-08-10 | 1603454 | CELC | 10-Q | Url |
| 2020-05-07 | 1603454 | CELC | 10-Q | Url |
| 2020-03-13 | 1603454 | CELC | 10-K | Url |
| 2019-11-07 | 1603454 | CELC | 10-Q | Url |
| 2019-08-08 | 1603454 | CELC | 10-Q | Url |
| 2019-05-07 | 1603454 | CELC | 10-Q | Url |
| 2019-03-01 | 1603454 | CELC | 10-K | Url |
| 2018-11-13 | 1603454 | CELC | 10-Q | Url |
| 2018-08-09 | 1603454 | CELC | 10-Q | Url |
| 2018-05-14 | 1603454 | CELC | 10-Q | Url |
| 2018-03-15 | 1603454 | CELC | 10-K | Url |
| 2017-11-13 | 1603454 | CELC | 10-Q | Url |
| 2017-08-23 | 1603454 | CELC | S-1 | Url |
Celcuity Inc(NASDAQ:CELC) 
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's c...
Website: http://www.celcuity.com
Founded: 2011
Full Time Employees: 27
Founder: Brian Sullivan / Lance Laing
CEO: Brian Sullivan
Sector: Healthcare
Industry: Diagnostics & Research
The information provided in this report about CELC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.